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Abstract: The report stresses the continuing increase in disease burden 
of liver disease from excess alcohol consumption and obesity, with high 
levels of hospital admissions and a worsening in deprived areas. Only 
with comprehensive food and alcohol strategies based on fiscal and 
regular measures such as the Minimum Unit Price (MUP) for Alcohol, does 
the Commission believe this can be curtailed, a view held by many other 
bodies too. The major contribution of obesity and alcohol to the high 
rates of the ten most common cancers is again stressed. The latest audit 
analysis adds yet further evidence of unacceptable levels in mortality 
for severely ill patients with liver disease in District General 
Hospitals (DGHs). A masterplan for improving hospital care, based around 
specialist hospital centres linked to DGHs by Operational Delivery 
Networks (ODNs), has been worked on further this year but continues to 
await approval by NHS England (NHSE). The value of day-case care bundles 
to reduce high hospital readmission rates with greater care in the 
community is shown again, with examples of locally derived schemes for 
the early detection of disease and in particular schemes to allow general 
practitioners (GPs) to refer patients directly for Fibroscan assessment. 
New funding arrangements will be required if these are to be taken up 
more widely around the country. 
 
A new ComRes poll, to be published in autumn 2019, shows an appalling 
lack of understanding of harm to health from lifestyle causes, with a 
poor knowledge of alcohol consumption and dietary guidelines. The 
Commission has serious doubts as to whether the initiatives described in 
the Prevention Green Paper, with the onus placed on the individual based 
on the use of information technology and the latest in behavioural 
science will be effective. The final section of the report raises 
questions of meaningful survival in paediatric liver disease where 
despite excellent overall survival results, there are high levels of 
cognitive impairment. 
 
Not included are the continuing efforts to eradicate hepatitis C virus 
(HCV) infection based on the extension of treatment by the new antiviral 
drugs to previously unidentified patient groups. Hepatitis B Virus (HBV) 
infection is also not considered as the efficacy of the new potentially 
curative agents remains to be established in multi-centre clinical 
trials.  
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Executive Summary 
 
The report stresses the continuing increase in disease burden of liver disease from excess alcohol consumption and obesity, with 
high levels of hospital admissions and a worsening in deprived areas. Only with comprehensive food and alcohol strategies based 
on fiscal and regular measures such as the Minimum Unit Price (MUP) for Alcohol, does the Commission believe this can be 
curtailed, a view held by many other bodies too. The major contribution of obesity and alcohol to the high rates of the ten most 
common cancers is again stressed. The latest audit analysis adds yet further evidence of unacceptable levels in mortality for 
severely ill patients with liver disease in District General Hospitals (DGHs)(1). A masterplan for improving hospital care, based 
around specialist hospital centres linked to DGHs by Operational Delivery Networks (ODNs), has been worked on further this 
year but continues to await approval by NHS England (NHSE). The value of day-case care bundles to reduce high hospital 
readmission rates with greater care in the community is shown again, with examples of locally derived schemes for the early 
detection of disease and in particular schemes to allow general practitioners (GPs) to refer patients directly for Fibroscan 
assessment. New funding arrangements will be required if these are to be taken up more widely around the country. 
 
A new ComRes poll, to be published in autumn 2019, shows an appalling lack of understanding of harm to health from lifestyle 
causes, with a poor knowledge of alcohol consumption and dietary guidelines. The Commission has serious doubts as to whether 
the initiatives described in the Prevention Green Paper(2), with the onus placed on the individual based on the use of information 
technology and the latest in behavioural science will be effective. The final section of the report raises questions of meaningful 
survival in paediatric liver disease where despite excellent overall survival results, there are high levels of cognitive impairment. 
 
Not included are the continuing efforts to eradicate hepatitis C virus (HCV) infection based on the extension of treatment by the 
new antiviral drugs to previously unidentified patient groups. Hepatitis B Virus (HBV) infection is also not considered as the 
efficacy of the new potentially curative agents remains to be established in multi-centre clinical trials.  
 
Introduction 
 
Although in last year’s report I spoke optimistically of a gathering momentum, this year I can only report a series of ongoing 
failures. This is despite even more media attention on the harmful effects on health resulting from lifestyle causes. The 
broadcaster Adrian Chiles, who had learnt of the dangers of heavy drinking before it was too late, has been powerful in advocacy 
and was instrumental in the BBC Panorama programme in June, directed at the lobbying power of the drinks industry and its 
influence on Government policy. Sadly, the past 12 months have seen no progress in Government instituting the regulatory and 
fiscal measures which are the only proven way to control overall alcohol consumption in the country. In its recently published 
Green Paper “Advancing Our Health: Prevention in the 2020s”(2), although a acknowledging the extraordinarily high levels of 
overweight and obesity in the population, Government seems to be mainly concerned with tackling childhood obesity and for 
adults with obesity, the only funding commitment is for diabetes care. It is reviewing what is covered in the NHS Health Check, 
making it more focused on individual risk factors. NHSE has announced new funding for alcohol care teams in hospitals(3) with 
the highest levels of admissions due to alcohol dependency. But, with one in five patients in UK hospitals consuming alcohol at a 
harmful levels and one in ten alcohol dependant(3), this will need to be extended to many more hospitals. The first analysis of 
MUP in Scotland has confirmed the value of this measure in reducing the intake of heavy drinkers, with a 3% fall in alcohol sales 
to adults compared to a 2% increase in England (4). 
 
Not surprisingly, with the continuing rise in hospital admissions of severely ill liver disease patients, adequate care and facilities 
continue to lag behind. Further work this year has gone into developing a hospital masterplan based on networks of DGHs linked 
with specialist liver centres. But as indicated in this section of the report, the proposals await final endorsement by NHSE. Results 
are given on the wider use of Fibroscan by GPs in screening for early liver disease, shown to be worthwhile in terms of diagnosis 
of cirrhosis cases. On a negative note are the cuts in community addiction and treatment services as a result of reductions in public 
health funding. 
 
A worrying new finding in the report relates to occurrence of neurocognitive impairment in infants and children with liver disease, 
raising issues over meaningful life outcomes. Also new to the Commission’s work this year is a ComRes poll on public awareness 
of liver disease. For me, the one encouraging event was a recent National Institute for Health Research (NIHR) broad call for 
research projects of a translational nature in liver disease encompassing many of the recommendations that have been made by the 
Lancet Commission. 
 
Alarming Lack of Public Awareness: Results of the ComRes Poll 
Polling by ComRes between 24
th
 and 27
th
 May 2019 of 2,016 British adults aged >18years, exposed an extraordinary lack of 
knowledge about liver disease. Almost one third (32%) of respondents wrongly believed the burden and number of deaths caused 
by liver disease in the UK are falling year-on-year. Only one in ten (11%) can correctly identify all three main causes of liver 
disease, whilst a quarter (26%) mistakenly think smoking is one of them. 
 
89% correctly identify drinking harmful levels of alcohol as part of the official drinking guidelines, but wrongly identified the 
weekly limit for men and women as over 14 units. In addition, 61% of respondents consider it possible to drink higher than 
recommended levels of alcohol for years without noticing any apparent harm to their health. 57% of alcohol drinkers claim their 
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current level of consumption has no impact on their health, whilst just a quarter (26%) recognise it has a negative impact. Only 
43% of respondents agreed that labels on alcoholic drinks currently contain enough information on the health risks for the public 
to make informed choices, emphasising the need for more accurate and comprehensive labelling of alcoholic beverages. 
 
Just two in five (40%) British adults rightly identify obesity as one of the three main causes of liver disease. To combat obesity, 
there is overwhelming public support for reducing the sugar content in foods (77%) and making healthy food and drinks cheaper 
than unhealthier ones (81%). 
 
Figure 1: Summary of Key Findings of the ComRes survey  
 
 
BURDEN OF LIVER DISEASE  MAIN CAUSES OF LIVER DISEASE 
In the UK, the disease burden and deaths caused by liver 
disease are falling year-on-year: 
  
True: 32% 
False: 68% 
  
Which are the three main causes of liver disease?* 
  
Alcohol misuse: 89% 
Obesity: 40% 
Viral hepatitis: 35% 
All three above correctly selected: 11% 
Smoking: 26% 
  
*Based on prompted responses, including a range of other options 
included in the survey (not listed: inherited genetic factors, blockages 
to the gallbladder, lack of iron in the diet, sleep deprivation) 
  
MISCONCEPTIONS ABOUT ALCOHOL MISUSE 
“You can drink higher than recommended 
levels of alcohol for years without 
noticing any apparent harm to your 
health”: 
  
True: 61% (N.B. correct answer) 
False: 39% 
  
  
  
Estimated number of units per week 
as the official level for low-risk 
drinking according to the UK Chief 
Medical Officers’ guidance: 
  
14 units: 16% (N.B correct answer) 
More than 14 units: 13% 
Less than 14 units: 39% 
Do not know: 33%  
How, if at all, do you consider your current level 
of alcohol consumption to impact your health? 
Of those who drink alcohol (n=1,660) 
  
No impact: 57% 
Negative impact: 26% 
Positive impact: 14% 
 STEPS TO COMBAT ALCOHOL MISUSE AND OBESITY 
To what extent, if at all, do you support or oppose each of the 
following measures aimed at reducing obesity? 
 
“Reducing the sugar content in foods” 
  
Net support: 77% 
Net oppose: 8% 
Do not know: 4% 
  
Making healthy food and drinks cheaper than unhealthier 
ones: 
  
Net support: 81% 
Net oppose: 4% 
Do not know: 5% 
  
To what extent, if at all, do you agree or disagree with each of the 
following? 
 
“Labels on alcoholic drinks contain enough information on health risks 
for the public to make informed choices” 
 
Net agree: 43% 
Net disagree: 28% 
Neither agree nor disagree: 22% 
Do not know: 8% 
 
“More calorie information on labels of alcoholic drinks would help 
consumers make more informed choices” 
 
Net agree: 52% 
Net disagree: 20% 
Neither agree nor disagree: 23% 
Do not know: 5% 
 
ComRes interviewed 2016 British adults aged >18yrs online between 24
th
 - 27th May 2019. Data were weighted by key 
demographics including age, gender, region and social grade in order to be representative of all British adults. ComRes is a 
member of the British Polling Council and abides by its rules. Full data tables are available from www.comresglobal.com   
 
Continuing High Alcohol Consumption and Disease Burden  
Data from the Office for National Statistics shows that in 2017, 57·0% adults aged 16 years and over drank alcohol in the week 
before being interviewed which equates to 29·2 million people in the UK (Figure 2). The recent Monitoring and Evaluating 
Scotland's Alcohol Strategy (MESAS) report (5) on the effects of introduction of MUP, showed a 2% overall increase in alcohol 
sales in England compared with a 3% reduction in Scotland. 
 
 
 
 
 
Figure 2: Self-reported drinking habits in the week prior to interview, Great Britain 2005-17(6) 
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The study of Roberts et al across England and Wales from 2004 to 2012 (1) has shown mortality rates following acute admission 
of 23·4% overall and 35·4% for those with hepatic failure at 60 days after admission, seven times higher than following acute 
admissions with stroke and eight times higher than for acute myocardial infarction (MI). Mortality was significantly lower for 
patients seen by consultant hepatologists and gastroenterologists and for patients admitted to transplant centres or larger hospitals. 
At five years following admission, mortality was 61·8% with alcoholic liver disease and 57·1% for hepatic failure (Figure 3). A 
recent meta-analysis(7) suggests that the true prevalence of alcohol-related conditions in NHS hospitals is approximately 20-30 
times higher than the official government statistics (ie 24-36million per annum), most likely due to an lack of training of staff in 
the NHS to identify, diagnose, treat and record the number of people with alcohol related conditions(7). 
 
 
Figure 3: Mortality rates following admission with alcoholic liver disease and hepatic failure 2004-2012  (1) 
 
 
 
permission requested 
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Analysis of data from a large teaching hospital in the South of England showed no evidence of improvement in survival of 
cirrhosis admissions over the last 15 years (Figure 4), echoing the results of an older study which showed no improvement 
between 1959 and 1976 (8). In previous reports, we presented analysis of Dr Foster data showing that in-hospital mortality for 
liver disease is consistently falling year on year. But the fact that improvements in hospital care have not translated into 
improvements in long-term survival of cirrhosis patients is a terrible reflection of current UK practice when all the advances in 
care introduced are considered. Relevant to this is the finding that the majority of patients with cirrhosis are not picked up in 
primary care but remain undiagnosed until the first admission to hospital with complications of cirrhosis. Around one third die 
within months of first presentation and furthermore, it is clear that the legacy system of arranging cirrhosis follow-up in secondary 
care is also not fit for purpose. We analysed liver follow-up in the cirrhosis cohort (Figure 4) where the hospital policy was to 
review every cirrhosis patient at six monthly intervals in order to arrange endoscopy and ultrasound surveillance, in compliance 
with NICE guidelines. The analysis found that of 3010 cirrhosis patients, 13% only had been seen in clinic within the last six 
months and 73% had not been seen for three years; 47% had never been seen at all. Only 37% had a record of liver ultrasound 
within the last year and 37% had not had an endoscopy with the last three years.  
 
 
Fig 4: Survival of patients following first admission with a diagnosis of cirrhosis categorised into three year cohorts 
 
 
Data was extracted from the Patient Administration System (PAS) at University Hospitals Southampton for consecutive 
admissions with a primary or secondary diagnosis of cirrhosis according to ICD 109 coding. Date of death is regularly updated to 
the PAS system from the national Mortality Tracing Service and enabled survivals to be calculated and a Kaplan Meier survival 
analysis to be performed. Data obtained from several other large UK liver centres previously is not presented but showed a similar 
picture. 
 
 
Alcohol Care Teams and Community Alcohol Services 
The NHS long-term plan, published in January 2019(3), includes a commitment to establish and optimise alcohol care teams 
(ACTs) in district general hospitals over the next five years.  NHSE and NHS Improvement (NHSE&I) will be targeting the worst 
affected hospitals with additional monies(3).
 
Funding will come from the clinical commissioning groups’ health inequalities 
funding supplement, working in partnership with local authority commissioners of drug and alcohol services from 2020/21.In 
addition, a £4.5 million innovation fund was launched in 2018 by the Department of Health and Social Care for local projects 
working with children and families affected by alcohol(9). NHSE will be providing guidance on implementing ACTs. Moriarty 
identifies eleven components as essential in ACTs (see Box 1)(10). In a 2009 survey of ACTs in London hospitals, only 42% had 
an alcohol support nurse (ASN) and 10% a lead clinician(11).
  
Encouragingly, in 2016, 83% of UK hospitals had ASNs(12), and 
in 2019, around 60% have a clinician lead although many hospitals are still not staffed to provide a 7-day ASN service. 
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Box 1:  Key components of Alcohol Care Teams(10) 
1. A clinician-led, multidisciplinary alcohol care team, with integrated alcohol treatment pathways across primary, 
secondary and community care; 
2. Coordinated alcohol policies for emergency departments and acute medical units; 
3. A 7-day alcohol specialist nurse service; 
4. Addiction and liaison psychiatry services; 
5. An alcohol assertive outreach team for frequent hospital attenders; 
6. Specialist consultant hepatologists and gastroenterologists with expertise in liver disease; 
7. Collaborative, multidisciplinary, person-centred care; 
8. Quality metrics, national indicators and audit; 
9. Workforce planning, training and accreditation; 
10. Research, education and health promotion for the public and healthcare professionals; 
11. Formal links with local authority, public health, clinical commissioning groups, patient groups, and other key 
stakeholders. 
 
The 9% of people in England with alcohol dependence who are frequent alcohol-related hospital attenders account for 59% of all 
alcohol-attributable hospital admissions has(13). Alcohol assertive outreach treatment (AAOT) for the estimated 54,369 patients 
in England with alcohol-attributable hospital admissions has an implementation cost of £161 million, with cost savings of around 
£575 million, the return on investment (ROI) being £3·42 for every £1 spent(14) and also strongly correlates with the index of 
multiple deprivation (r=0·74)(14).
 
With the emphasis of the prevention Green Paper on reducing health inequalities, the 
Commission’s view is that ACTs and AAOT should be rolled out to all DGHs with a demonstrated patient burden of alcohol-
related illness. This would facilitate achievement of the United Nations General Assembly Sustainable Development Goals 
(SDGs), especially SDG 10, which aim to reduce global health inequalities and provide a more equitable and sustainable future 
for all people by 2030. 
 
The alcohol and tobacco CQUIN (Commissioning for Quality and Innovation) was introduced in 2017 and is being implemented 
across all inpatients in mental health, community and secondary care NHS trusts(15). Latest data shows that overall, 25·2% of 
screened inpatients are drinking at increasing/higher risk/possible dependent levels in mental health trusts, 14·2% in acute trusts, 
and 6·4% in community trusts (personal communication). These figures compare to 25% of the general population who are 
drinking at increasing and higher risk levels and dependence. 
 
Reduction in community treatment and addiction services 
Since the introduction of the Health and Social Care Act, combined with cuts to the government’s Public Health Grant to local 
authorities, there has been an 18% (£162million) reduction in funding to community addiction treatment services in England, with 
ten local authorities reducing by at least 40%(16)
 
 resulting in a 22% reduction in the number entering specialist alcohol treatment, 
and a 52% reduction in access to specialist inpatient alcohol detoxification(16). England now has less than half the level of access 
to specialist alcohol treatment compared to Scotland and Wales (Table 1). 82% of people with alcohol dependence do not 
currently access specialist treatment(16). 
 
Table 1: Alcohol treatment access ratios across the United Kingdom 2017/18 compared to 2016/17 
Country Number 
accessing 
treatment for 
alcohol only
1 
Number of F10 
alcohol hospital 
admissions
2 
Rate of F10 
admissions 
/100,000 
population >18 
years 
Treatment access 
ratio (F10 
admissions/ 
treatment access)
3 
Treatment 
access ratio 
(17)
 
Scotland 26,107 27,025 614·9 1·0 1·1 
Wales 7,678 8,804 307·5 1·1 1·2 
England 75,787 197,460 451·3 2·6 2·4 
Northern Ireland 2,577 9,963 694·6 3·9 3·9 
United Kingdom 112,149 243,252 467·0 2·2 2·1 
 
1
Excludes concurrent drug misuse as a reason for treatment. 
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2
Primary or secondary diagnosis of ICD10 F10 ‘Mental and Behavioural Disorders due to Use of Alcohol’. This is a proxy 
measure of the prevalence of alcohol dependence in the general population. 
3
Note the treatment access ratio - the number of F10 admissions to NHS hospitals divided by the number of people accessing 
specialist alcohol treatment – which worsened in England and the UK as a whole. 
 
 
Another consequence of the cuts has been a 48% reduction in the number of NHS specialist addiction consultants in England, and 
a 60% reduction in the number of specialist addiction trainees(18).  
 
Public Health England (PHE) announced in March 2019 a £6 million capital fund to enable local authorities to invest in improving 
access to alcohol treatment services and of the 23 projects commissioned, seven comprised purchase of FibroScan machines to 
enable rapid identification of liver disease(19).
 
 
Need for a Comprehensive Strategy to Reduce Alcohol Consumption 
Not only are alcohol related deaths rising(20) but the number of people harmed by someone else’s drinking is estimated at one-in-
five according to a recent Public Health England (PHE) report(21). Much evidence is available of effective solutions that could be 
adopted, with action on price, availability and marketing at the top of the list of interventions (22). The 50pence minimum unit 
price (MUP) of alcohol it is estimated would reduce alcohol attributable deaths in England by 4·3% and associated healthcare 
costs by 2·3%(23). Strong consensus exists amongst health, social care, justice and civil society groups that such measures are 
urgently needed to tackle alcohol harm(24). A comprehensive alcohol strategy by Government should follow the 
recommendations of WHO and tackle the affordability, availability and promotion of alcohol, aiming for a 10% reduction in 
harmful use of alcohol by 2020(25).  
 
The UK Government has repeatedly failed to grasp many opportunities to take meaningful action to prevent alcohol harm. Plans 
for a UK alcohol strategy announced in May 2018(26) have been put on hold whilst the Chancellor of the Exchequer has made 
alcohol more affordable by cutting duty in the October Budget 2018(27) (a decision that resulted in a loss of £1billion to HM 
Treasury, equivalent to the annual salaries of 40,000 nurses(28). A 2% above inflation increase in alcohol duty would result in 
4,710 fewer alcohol related deaths and 160,760 fewer hospital admissions between 2020-2035, according to the latest modelling 
report(29), as well as raising substantial funds to support over-stretched local public health budgets.  
 
The Government’s Prevention Green Paper(2), whilst acknowledging that alcohol harm is rising, made no commitment to address 
the major drivers of ill-health and inequality linked to alcohol(2), devoting only one and a half pages of the 78 page document to 
alcohol consumption. No actions were proposed to target the 4% of the adult population who are the heaviest drinkers that account 
for 30% of all alcohol consumed. The Department of Health and Social Care (DHSC) are reviewing the evidence to consider 
increasing the alcohol-free descriptor threshold from 0·05% ABV to 0·5% ABV(2). Such a move, however, will have no impact 
whatsoever on the high-risk drinkers who are most in need of specialist treatment and support services.  
 
Another opportunity for Government to act in the interests of public health was the 1
st
 September 2019 deadline given to alcohol 
companies to display up to date and accurate information on product labels about the health risks associated with alcohol(30). The 
majority of drinks sold do not carry the latest Chief Medical Officer’s low risk drinking guidelines, leaving consumers in the dark 
about the latest health advice(31). In August 2019, a month before the Government’s deadline to display the guidelines on labels, 
the alcohol industry’s Portman Group announced it was ‘encouraging’ its members to display the CMO advice on product 
labels(32) but no timelines were offered for implementation.. 
 
Disease Consequences of High Obesity Prevalence 
In 2017, the figure for obesity in adults was 29%, a 3% annual increase, whilst for children in Year 6 and Reception the figures 
were 20·1% and 9·5% respectively. Of particular concern is the increasing gap in obesity prevalence between the least and most 
deprived deciles, with a five percentage point increase for Year 6 children between 2006/07 and 2017/18(33). Obesity related 
disorders remain a major contributor to hospital workload, with 10,660 admissions directly attributable to obesity and over 
700,000 admissions where it is a primary or secondary diagnosis (a 15% annual increase). The 6,627 admissions for bariatric 
surgery in 2017/18 are an increase of 2% over the previous year(33) but represent treatment of less than 2% of eligible 
individuals. Type 2 diabetes, of which obesity is the major cause, now affects over 3 million people in the United Kingdom, of 
whom 22,000 die prematurely every year and diabetes is responsible for almost £9 billion of costs to the NHS every year, around 
9% of the total NHS budget(34). End-stage non-alcoholic fatty liver disease (NAFLD) is also posing an increasing burden on 
transplant services(35).  
 
The Chief Medical Officer annual review, to be published in autumn 2019, is likely to identify key actions required to achieve the 
government’s ambition to halve child obesity by 2030 and the Department of Health and Social Care has consulted on some of the 
main proposed policy actions(36, 37) in Chapter 2 of the Child Obesity Plan in 2018(38). The recently published Green Paper on 
Prevention(2) contains a range of proposals including labelling, food reformulation, weight management services and physical 
activity promotion but gives little guidance on how these will be translated into effective policies which will require much more 
intensive policy action than has been seen to date (39). The only new regulatory commitment was to consult on ending the sale of 
energy drinks to the under 16yrs age group. The persistent framing of obesity as the result of individual choice needs to be 
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challenged; obesity is primarily driven by environments that promote over-consumption of food and under-expenditure of energy 
and it is only by tackling obesogenic environments that equitable reductions in prevalence and consequent health benefits will be 
obtained. 
 
Marketing of Unhealthy Food and Alcohol  
There is unequivocal evidence that the marketing of unhealthy food to children leads to childhood obesity (40) and that marketing 
of alcohol leads to an uptake of drinking and increased consumption in young people (41). Similar evidence for the marketing of 
cigarettes and smoking in young people led to comprehensive and effective global bans on tobacco as part of the International 
Framework Convention on Tobacco Control (42). In contrast, the food and alcohol industries have been allowed to ‘self-regulate’ 
despite evidence that this does not effectively reduce childhood exposure to adverts (43). In an increasingly digital age - children 
aged 12-15yrs are online for an average of 21 hours each week in the UK (44) - teenagers are exposed to promotional activities 
which include paid-for advertisements, product placement, content sharing by peers or the activities of social media influencers. 
These targeted messages are then narrowcast to mobile devices without parental control or oversight. Young people cannot always 
recognise these marketing tactics as having a commercial goal or distinguish them from organic(45). The spend on digital 
marketing has increased year on year, in 2016 receiving the largest share of advertising spending in the UK(46). 
 
Social media and other operators have created sophisticated datasets to target consumers but between the commercial operators 
with products to sell and their young target audience, marketing messages disappear into a black box marketplace where 
individual messages are sold on by a myriad of intermediate agencies – supply-side platforms, data exchanges and demand-side 
platforms - which bid for advert impressions (47). Though advertising messages could be tagged and traced, there is no facility to 
do this within the current marketplace. Effective forms of age verification do exist but these are not currently used to filter 
marketing traffic with the result that no one knows if a marketing message is seen by a child or an adult. 
 
Earlier this year the World Health Organisation published an outstanding report including pragmatic solutions (47), the CLICK 
tool providing the conceptual framework needed to understand and monitor exposure of children to digital messages(40). Along 
with estimating exposure, WHO suggest there should be effective age verification and message tagging, coupled to achieve 
effective regulatory regimes. Policy makers need to be made aware that the digital marketplace in the UK is almost entirely un-
regulated and mandatory Government measures to reflect this unique environment are urgently needed.     
 
Overweight and Obesity, and Alcohol Consumption as Cause of Common Cancers 
In the UK, 38% of the 22,800 cancer cases annually are preventable(48) including 49% of liver cancer cases (around 2,800 cases). 
Overweight and obesity (body mass index [BMI] 25+) contribute the highest proportion of liver cancers (around 1,300 cases 
annually) and is second only to smoking as the leading preventable cause of cancer in the UK, with alcohol consumption ranking 
sixth(48). Overweight and obesity have a definite causal link with 13 cancer types, while alcohol  consumption is linked with 
seven cancer types(49, 50).  
 
Figure 5a: Cancer types associated with      Figure 5b: Cancer types associated with  
overweight & obesity    alcohol drinking 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5a and 5b produced by Cancer Research UK and reproduced with the charity’s permission. 
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Most cancer types have multiple risk factors; liver, oesophagus, breast and bowel cancers are associated with both obesity and 
alcohol and there is evidence that obesity and alcohol combined have a synergistic effect on liver cancer risk(51, 52). Figure 5a 
and Figure 5b show the cancer types associated with overweight and obesity and alcohol drinking, with larger circles indicating 
higher number of cases attributable to the risk factor.  
 
 
Latest Situation in the Four Nations 
Minimum Unit Price for alcohol at 50pence per UK unit (10mls/8g) was introduced in Scotland on 1
st
 May 2018 and NHS Health 
Scotland has published sales data for 2018, covering four months pre- and 8 months post MUP.  Annual sales per adult at 9.9 litres 
pure alcohol(5) are now at the lowest level since the data series began in 1994. In 2016, per adult sales in Scotland were 17% 
higher than in England and Wales whereas in 2018 this gap had narrowed to 9%. A continuing issue is that sales data for Scotland, 
as with the rest of the UK, is not comprehensive with some retailers - including the discount supermarkets - not submitting data to 
market research firms. Scottish Health Action on Alcohol Problems (SHAAP) has called for a system where there is a legal 
requirement for sales data to be provided. Published annual mortality data for 2018 (53) showed a 1% increase in all alcohol 
specific deaths with the 3% reduction in alcohol sales. The 2019 mortality data which will become available in mid-2020, would 
be expected to have fallen.  Zhao and colleagues working with Canadian data estimated that the full effect of price increases on 
mortality are seen after 3 years(54). 
 
With the early identification of liver fibrosis fundamental to reducing progression of cirrhosis, the Scottish Government has 
adopted the “intelligent LFT system” (iLFT). The automated reflex testing system piloted in NHS Tayside(55) performs 
aetiological screening and fibrosis staging on bloods found to have abnormal LFTs on routine testing(4) and is now being rolled 
out across Scotland.  
 
In Wales, implementation of legislation for Minimum Unit Price has been delayed due to an objection made to the European 
Commission by Portugal and the plan is to introduce it in early 2020. The Irish Republic has passed a comprehensive alcohol Bill 
(56) including marketing restrictions and MUP but no implementation date has been set and new legislation in Northern Ireland is 
not expected until devolved Government is re-established. 
 
View of Commission Members on the Government’s Prevention Green Paper (2) 
The comments of two members of the Commission which are quoted in full and reflect the majority of views expressed 
personally: “In July 2019 the Department of Health and Social Care finally, and very reluctantly, published its Green Paper on 
prevention Accounts from Whitehall insiders report how the Health Secretary  sought to withhold it and then when Theresa May, 
Prime Minister at the time, decided it should be published, sought to have the Department’s name removed.  Unusually, when it 
did appear, it was not accompanied by a press release. The widespread scepticism with which it was greeted(57) has been 
encouraged by news that the new Prime Minister has appointed advisers linked to lobby groups funded by manufacturers of 
harmful products(58). 
  
The section on alcohol begins by saying that “Most people who drink, do so responsibly”. A recent study examined how the 
concept of responsible drinking is almost exclusively used by the alcohol industry and groups it funds(59). Until now, this term 
very rarely appeared in government documents. That study also found that it was often used in a context where government 
guidelines were being undermined and where the alcohol industry was portrayed as pursuing corporate social responsibility. 
 
The government’s proposals are extremely weak and ignore the evidence favouring population-based measures, such as taxation, 
reductions in availability, and restrictions on marketing which, as shown in the previous Lancet Commission on Liver Disease, 
are all strongly opposed by the alcohol industry.(17) There are three main proposals. The first is to make people more aware of 
alcohol-induced harms through Public Health England’s One You campaign(60). The second is to stress the value of an alcohol 
risk assessment in the NHS Health Check, another initiative criticised for lacking evidence of effectiveness(61). The third is the 
support children with alcohol dependent parents although, surprisingly for a consultation document, this has already been 
launched, in April 2018. A final section discusses collaboration with the alcohol industry to promote low alcohol products, 
without reference to the experience of the heavily criticised industry partnership in the Responsibility Deals, and in a major 
concession to the industry, promises to review the potential to redefine “alcohol free” to allow up to ten times the current level of 
alcohol. In summary, this is a document that could easily have been written by the alcohol industry and is almost wholly devoid of 
a public health perspective.” 
  
“The Government’s recent Prevention Green Paper is framed in terms of individual responsibility and personalised approaches, 
diverting focus away from the commercial and structural drivers of ill health in the population that so urgently need to be tackled. 
However, there are some positives including proposed actions on obesity which represent solid work by the DHSC and PHE 
obesity teams but it goes nowhere near far enough.”  
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Planned Proposals to Improve Hospital Based Care   
The Hepatobiliary Clinical Reference Group (HPB CRG) which advises NHSE on the management of patients with advanced 
liver disease has made a number of recommendations for major changes in response to the increasing volume of patients with 
cirrhosis and variation in outcomes between providers. The complexity of managing patients with acute on chronic liver failure 
and decompensated cirrhosis requires an experienced, diverse clinical team with 24-hour care provided by specialist hepatologists 
supported by appropriately trained intensivists, radiologists, dieticians, nurses and pharmacists as well as ready access to liver 
transplantation services. Such services cannot be provided in every hospital which admits patients with cirrhosis and to ensure that 
all patients have equal access to high quality care, the CRG has recommended that regional networks are established with each 
hospital linked to a centrally supported specialist centre. This will require the establishment of a comprehensive series of networks 
with appropriate funding and support and is strongly recommended by the Commission.  
 
To facilitate the development of networks the HPB CRG have recommended a new service specification for specialist providers of 
liver services which should lead to the development of a more targeted referral pathways. Patients with advanced liver disease 
admitted to any hospital in the country would receive early, algorithm based, review (including the use of the well-established 
‘cirrhosis care bundle’) followed by discussion with the local liver lead and, if appropriate, with the regional liver centre.  
 
An example of this is in East London. A Barts Health NHS Trust hepatology consultant is based at Queens Hospital in Romford 
and provides out-patient and in-patient advice on specialist liver care for the region. Furthermore, to improve current provision of 
care for patients with decompensated cirrhosis, NHSE has offered  a new incentive scheme (CQUIN) which rewards trusts who 
introduce new network based approaches to the management of patients with cirrhosis (62). Monitoring and evaluation of the 
changes will be through a new ‘Cirrhosis Dashboard’(63) which provides information on a range of metrics relating to the quality 
of care for patients with liver disease and will be sent to trust chief executives every quarter.  
 
At present 40 trusts are commissioned to provide specialist liver services and an analysis of data from the NHSE cirrhosis 
dashboard from June 2018 to April 2019 showed that a large number (over 120) are continuing to manage patients with cirrhosis 
although many report relatively small numbers of patients – 20 trusts admitted fewer than ten patients a quarter to HDU/ITU and 
76 trusts admitted fewer than 20 such patients. An average of 7·5% of patients with decompensated liver disease admitted as an 
emergency died in hospital with mortality being 8% in non-specialist trusts compared to 6·6% in the commissioned, specialist 
centres. Emerging therapeutics (such as next generation anti-inflammatories for alcoholic hepatitis) and technologies (including 
the long-awaited development of ‘liver assist’ devices that deliver meaningful benefits) are likely to further enhance the 
differences in outcomes between the high and low volume centres.  
 
No Increase in Liver Transplants 
1003 liver transplants in 2018-2019 (64) represent a reduction in activity compared with the 2017-18 total of 1043. 
Disappointingly also, with the potential for machine perfusion to increase the number of utilised organs, only 8% (63) of adult 
deceased donor first liver transplants were reported to have involved normothermic or hypothermic machine perfusion, with no 
use of it in two centres. At the end of 2018-19, the waiting list had risen by 20% (432 from 359) and during 2016-17, 10% of new 
elective patients listed for liver transplantation, died or had to be removed from the list. 
 
The three monthly reviews of the National Liver Offering Scheme (NLOS) introduced in March 2018 for brain death donor 
(DBD) organs based on a possible transplant benefit score at five years, showed a fall in the median waiting time for 
transplantation to 39 from 72 days but the acceptance rate of offers made through the scheme to specific matched recipients was 
lower than predicted at 30%. This has been accompanied by an increase (8% to 28%) of DBD livers not accepted for named 
recipients. New patients added to the waiting list since the inception of the scheme are more likely to be transplanted and as 
predicted by the modelling exercise, there is an undesirable trend towards older patients being transplanted and a reduction in 
those with HCC.  
 
Results of the soft version, opt-out legislation introduced in Wales in 2018 are also disappointing with no increase in number of 
donor organs, though there has been some reduction in refusal rate by families. It was hoped that with the anticipated 
implementation shortly of opt-out legislation in England in spring 2020 and a wider uptake of organ perfusion strategies in 
increasing organ utilisation, the opportunity would be taken to tackle unmet needs for liver transplantation such as proposals on 
chronic liver failure, hilar cholangiocarcinoma and neuroendocrine tumours, but as yet no definite  proposals have been agreed. 
 
Although there is no approval for additional liver transplant centres, NHSE do allow aspirant market entrants to replace or add to 
the existing providers and a number of aspirant centres including Plymouth, Oxford and Liverpool are working towards this but 
none are as yet in place. 
 
 
Major Vacancies in Workforce of Consultant Hepatologists and Specialist Nurses 
The goal for an effective specialist hepatobiliary service is to have two hepatologists serving 250,000 people or 0·8 whole time 
equivalent (WTE) per 100,000 population. Based on recent (2017) estimates, 221 hepatologists or 306 gastroenterologists with an 
interest in Hepatology are leading these services although the number is variable across the UK, with Scotland, England, Northern 
Ireland and Wales having 0·39, 0·35, 0·22 and 0·08 hepatologists respectively per 100,000 population. Optimising levels of 
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consultant Hepatologists requires an increase to 528 WTE, equivalent to 222 more posts. For this, liver appointments (and 
funding) will need to be prioritised and the rate of consultant expansion improved beyond the 1·6% - 4·9% annually for 
gastroenterology in the past decade.  
Speciality training and accreditation in hepatology has lagged behind that for Gastroenterology for more than a decade. The ratio 
of specialist trainees in Hepatology to luminal gastroenterology trainees should, it is recommended, be increased from the current 
1 in 3 ratio, thereby enabling NHS Trusts to prioritise the filling of vacant posts. Even wider variation exists across UK in the 
number of liver nurse specialists whose remit needs to be expanded to include day-case paracentesis and transient elastography 
(TE) services at the interface of primary and secondary care. 
 
Improvement of Post-hospital Discharge Care  
Cirrhotic patients who survive an emergency admission to hospital with ascites are frequently readmitted within a month of 
discharge and while some readmissions are inevitable due to continued disease progression, many are potentially avoidable. An 
analysis of 120,000 cirrhosis admissions revealed ascites or hepatic encephalopathy (HE) to be the major predictors of unplanned 
readmission at 30 or 90 days(65). Readmissions are often attributable to patients’ insufficient understanding of their medications 
or early recognition of symptoms and both the American Association for Study of Liver Diseases (AASLD) and European 
Association for Study of the Liver (EASL) guidelines emphasise the importance of education (66). In one study, only 6% of HE 
patients and their carers understood the purpose of drug therapy or its side effects(67) and a survey of 150 cirrhosis patients found 
awareness of HE and its treatment was lower than for any other complication(68). The simple intervention of providing 
educational booklets and structured post-discharge care needs to be more widely adopted. 
 
The excellent results that can be obtained for large volume paracentesis (LVP) performed for diuretic refractory ascites as elective 
day-case procedures by trained Nurse Specialists, has been well documented. In Cambridge, this has saved over 500 bed-days per 
year, at greater convenience for the patients. Nurse-led paracentesis is also offered in other locations, including Brighton, Bristol, 
Cardiff, Gloucester, London, Newcastle, Plymouth, Portsmouth, Southampton and Truro and should be included in planned care 
strategies for all hospitals treating liver patients. The value of this is further shown by a recent analysis of over 13,000 people with 
cirrhosis in their last year of life, with day-case services giving lower costs and a lower probability of patients dying in hospital 
(69). The use of paper-based or electronic decision support tools, prompting hospital staff to follow guidelines, has been shown to 
increase the proportion of patients discharged on appropriate medications, leading to fewer readmissions (65) and the 
comprehensive cirrhosis “discharge care bundle” now being piloted also needs to be included.  
 
Increased Detection of Early Disease by Screening 
The online toolkit for GPs (70), co-ordinated by the Royal College of General Practitioners (RCGP) and funded by the British 
Liver Trust (BLT), continues to evolve with the recent addition of detailed GP commissioning recommendations for decision 
makers. It also includes, as highlighted in a national GP practice mailout, easily accessible information on latest national 
guidelines for interpretation of liver blood tests(71) and for use of Fibroscan or Enhanced Liver Fibrosis (ELF) measurement of 
fibrosis based on AUDIT scores. The updated toolkit also includes ‘quick link’ buttons for easy access to guidelines/tools during 
GP consultations. Incentivising evidence-based care based on quality improvements, along with working with newly formed GP 
Primary Care Networks (PCNs) and their access to central funding for social and lifestyle prescribing, as well as co-ordinating 
with local authorities represent further strong recommendations by the Commission.     
 
Inclusion of the early detection programme in an updated NHS Health Check  in line with NICE guideline NG50 Current Advice 
(72) will add significantly to the value of these checks. Exemplar proven models of care include the prizewinning Scarred Liver 
Project in Nottingham and the Southampton pilot pathway region-wide is leading to a reduction in hepatology referrals as well 
(http://www.stmaryssurgery.nhs.uk/info.aspx?p=10). These need to be rolled out more widely in an effective context across the 
country, as does the Tayside programme of Intelligent Liver Blood Tests (ILFTs) (55).  
 
 
Box 2:  The Scarred Liver Project, Nottingham 
 
The Nottingham pathway continues to attract significant numbers of referrals (>3000, since inception) with diagnosis of 
significant liver disease (>20%, TE >8kPa, ~10% cirrhosis). The pathway has evolved to allow GPs and patients greater access to 
transient elastography based on risk factors alone. Any patient with type 2 diabetes, obesity, incidental fatty liver on ultrasound 
and a BARD score >1, or alcohol excess, can now go straight to transient elastography without the need for prior liver blood tests. 
Supported by the local Academic Health Sciences Network (AHSN), the pathway has been adapted for trials in other areas 
included within community drug and alcohol services in Chesterfield and within a regional primary care ‘super-practice’ (served 
population 200k). The forward focus is on developing the brief lifestyle advice provided to all patients into a more supportive and 
sustainable behaviour change intervention.   https://www.scarredliverproject.org.uk/ (73) 
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Combination of Potential Risk Factors for Liver Disease in a Primary Care Sample  
With the proven evidence of a supra-additive, synergistic interaction between raised body mass index (BMI) and alcohol 
consumption in the development of liver disease(74), knowledge of the co-occurrence of both factors is of considerable relevance 
to health screening and public health policies. The Health Improvement Network (THIN), a large, representative database 
covering anonymised electronic medical records from over 700 general practices,  was used to identify the occurrence of higher 
risk drinking, raised BMI, and both risks, in an adult sample attending a GP appointment in the financial year 2017/18 (personal 
communication, Clive Henn). Over 50,000 patients were identified who could benefit from a brief AUDIT and 1,500 patients 
were both obese and drinking at high risk levels. True levels were thought to be substantially higher and such individuals, with 
their substantially increased risk of liver disease, should be prioritised for screening and management measures. 
 
Outcomes in Children with Liver Disease  
Death has become a rare outcome with mortality as low as 5% and is mainly in patients who were not candidates for liver 
transplantation or as a result of untreatable complications developing in later years after transplantation. An audit of all deaths 
occurring within the three UK paediatric liver centres (PLC) over the last five years (2014-2018) identified 137 deaths of whom 
28 had undergone liver transplantation.  Only four died of conditions unrelated to their liver disease. 76 of the 137 deaths were 
unexpected and such deaths remain a significant organizational issue, with 54% of deaths occurring outside the centres. It is 
recommended that all patients attending the three specialist centres should be reviewed for risk of death in childhood, allowing 
more focused treatment measures as well as palliative care to be planned.  
 
Poor Neurocognitive Ability  
Long-term outcome data of children with liver disease has highlighted poorer cognitive ability and inferior educational and 
employment outcomes.  Development is delayed, cognitive abilities are poorer and educational attainment is worse. More 
attention, the Commission recommends, needs to be given to the concept of ‘meaningful’ survival - a state of complete physical, 
mental, and social well-being and not merely the absence of disease. Consequent on this, employment, regarded as a health 
outcome, is inferior to that in the adult liver transplant population (25%) and other transplant cohorts such as renal transplant 
(Table 2). Identifying the risk factors associated with poor long-term neurocognitive outcomes will be essential in order to focus 
care on corrective measures. Special educational support, it is estimated, will be required in 42% of these children and young 
people.  
 
 
Box 3: Hepatology vs community-based referrals in Southampton Primary Liver Care Pathway, 2015-2019 
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Table 2: Employment outcome in paediatric liver transplant recipients and young people with autoimmune liver disease 
(data from Kings College Hospital, London, only and does not include the two other UK paediatric liver centres)  
 
 
 Active 
(employed 
+unemployed) 
Employed 
(% of total 
population) 
Unemployed  
(% of active 
population) 
Inactive/in 
education 
Paediatric liver transplant recipients 
(n=100) 
57% 35% 30% 43% 
Paediatric recipients >21 years after 
transplantation (n=69) 
72% 46% 36% 28% 
Autoimmune liver disease (n=54) 72% 64% 10% 28% 
 
 
 
Conclusions 
This report stresses once again the need for fiscal regulatory measures by Government to prevent harm by reducing alcohol 
consumption including the MUP and the alcohol duty escalator. The first results of its introduction in Scotland confirm how 
targeted MUP is on heavy drinkers, with a decrease in sales of low cost alcohol. The value of the levy on the sugar content of 
drinks, giving less than half the anticipated revenue to the Exchequer because of reformulation of products by the industry, is 
further evidence of what is achievable by fiscal initiatives. In the Commission’s view, without fiscal measures the chances of 
achieving 5 extra years of healthy living, as targeted by the Secretary of State for Health and Social Care, is unlikely. 
Furthermore, with the extraordinary lack of awareness of liver disease by the public shown in the new ComRes survey, putting the 
entire responsibility on the individual to control lifestyle excesses, as recommended in the Government’s recently published 
Prevention Green paper, is unlikely to be successful in comparison with population directed initiatives.  
 
The latest high mortality figures for severely ill liver patients admitted to DGHs are another reminder of the urgency on NHSE to 
implement the masterplan for hospital services based on regional specialist centres, each linked to networks of DGHs through 
operational delivery networks (ODNs). Along with this is the wider use of discharge care bundles for guiding further treatment as 
an outpatient day-case and reducing the high readmission rates. Finally, the effectiveness of an increasing number of locally 
driven schemes based on availability of a Fibroscan, show how important this is for the earlier detection of liver disease, with the 
need to include this in financial incentives on GPs as part of the Health Check. 
 
 
Box 4: The Commission’s Key Messages and Priorities for 2019-20 
 
Key Messages:- 
 Continued increase in harms from excess alcohol consumption and high overweight/obesity  
 Unacceptably high mortality for acutely sick liver patients admitted to District General Hospitals 
 Value of early detection programmes in general practice based on Fibroscan  
 An extraordinarily poor level of public awareness of liver health hazards (ComRes poll) 
Key Priorities:- 
 Convincing Government of need for fiscal regulatory measures including MUP, tax duty escalator and levies on food 
content 
 Implementation of Masterplan for hospitals and day-care treatments  
 A new focus on meaningful survival in paediatric liver disease  
 Making case to Government to set targets for reduction in 1) alcohol consumption and 2) adult overweight/obesity levels 
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